Renal cell carcinoma (RCC) is a common cancer that accounts for 2%-3% of all cancerous diseases in adults. 1 There are approximately 65 000 cases of RCC each year, and RCC is the eighth most common cause of cancer mortality. 2 RCC affects quality of life and life expectancy and has important health and economic implications related to metabolic syndromes, increased cardiovascular risk and end-stage kidney disease. 3 In addition, clear cell renal cell carcinoma (ccRCC) is the most universal subtype of RCC, accounting for approximately 75% of RCC. Furthermore, the morbidity and mortality rates of RCC are rising globally. 4 Besides traditional surgery, RCC is resistant to the other forms of therapies chemotherapy and radiotherapy. The 5-year survival rate of RCC is approximately 55%, while the 5-year survival rate of metastatic RCC is approximately 10%. 5 Patients with metastatic RCC are faced with a depressing prognosis and limited therapeutic options. The median survival time in a recent cohort study was only 1.5 years, and the survival rate was less than 10% in patients who survived 5 years. 6 Thus, it is vital to study the molecular basis of RCC to design novel therapeutic drugs to improve survival rates.
MicroRNAs (miRNAs) are 19-22 nucleotide-long non-coding
RNAs that function as negative regulators of translation and are involved in many cellular processes. Increased levels of specific miRNAs have been closely related to a variety of diseases, such as cancers, diabetes, obesity and cardiovascular disease. 7 miRNAs are non-coding RNAs, and it has been estimated that 30% of all genes in animals are regulated by translational and post-transcriptional repression, cleavage or destabilization. 8 miRNA dysregulation is an important component of this landscape, which relies on both the oncogenic and tumour-suppressive functions of miRNAs. Among miRNAs, the highly conserved let-7 family has a prominent role in regulating embryonic development and the maintenance of differentiated tissues. Let-7 is as a potent tumour suppressor via its post-transcriptional repression of multiple oncogenes including RAS, Myc and HMGA2. The let-7 family is downregulated in multiple tumour types and causally linked to oncogenesis. 9 miRNAs are also aberrantly expressed in several eukaryotic organisms to regulate the stability and processing of target mRNA through directly binding to 3′UTRs. miRNAs have been reported to be involved in cell proliferation, cell differentiation and cell apoptosis, resulting in a reduction in the microRNA levels of hundreds of small target mRNAs. 10 miR-203 is a tumour suppressor in a variety of human cancers, such as hepatocellular carcinoma (HCC), 11 prostate cancer 12 and liver cancer. 13 Besides, miR-203 can directly suppress the expression of transcription factor p63 during epidermal differentiation, thus limiting the proliferation potential and inducing the withdrawal of the cell cycle to eventually promote epidermal differentiation. 14 In rhabdomyosarcoma cells, the overexpression of miR-203 suppressed cell growth and promoted myogenic differentiation. 15 Currently, lncRNAs are differentially expressed in various tissues and have essential functions in gene regulatory processes in normal cells and cancer cells. Furthermore, many lncRNAs are associated with chromatin modification complexes and act as miRNA sponges, which adjust gene expression. 16 LncRNAs are the largest class of non-coding RNAs. Noncoding RNAs, once thought to be part of the transcriptional noise, now constitute a regulatory layer of transcriptional and post-transcriptional regulation. The enhanced transcriptional noise and gene expression regulatory function of lncRNAs are fully supported by their functional roles observed in various important biological environments. 17 In previous reports, high expression levels and the acute hypoxic induction of MALAT1 in several mouse organs suggested a hitherto unrecognized role of this lncRNA in systemic adaptation hypoxia. 18 In addition, the upregulation of MALAT1 was correlated with cancer progression and poor prognosis in clear cell renal cell carcinoma. 19 However, the roles of MALAT1 in RCC progression need to be further understood.
BIRC5 (also known as survivin) is a critical anti-apoptotic protein that is been involved in many cancer types. BIRC5 inhibits apoptosis-related signalling pathways and promotes cell proliferation to affect cancer progression. 20 BIRC5, which encodes surviving, is upregulated in both adenocarcinoma and squamous cell carcinoma tissues, and the high expression of BIRC5 is related to poor survival in adenocarcinoma, but not squamous cell carcinoma. In addition, survivin was identified as a candidate marker of aggressiveness in clear cell renal cell carcinoma (ccRCC), and high expression levels of survivin protein predicted a poor outcome for ccRCC patients. 21 In addition, the ratio of the miR-195 level to the BIRC5 level was associated with both recurrence-free and overall survival in lung adenocarcinoma. 22 Previous researches showed that the miR-195/BIRC5 axis is a potential target for the specific treatment of lung adenocarcinoma, especially for NSCLC (non-small-cell lung carcinoma). 22 BIRC5 is a new member of inhibitor of IAP family, the proteins of which regulate the cell cycle and apoptosis. Besides, the expression of BIRC5 was induced by hypoxia, 23 and BIRC5 promoted angiogenesis and was strongly correlated with cell proliferation. 24 There is increasing evidence that indicated that BIRC5 is highly expressed in most human tumours and closely related to tumour progression, tumour recurrence, chemotherapy resistance and poor prognosis. 25, 26 The aim of our study was to investigate the roles of MALAT1/ miR-203/BIRC5 in the development and progression of RCC, which might provide us with more diagnostic and therapeutic strategies for RCC in the future. OS-RC-2 cells were cultured in RPMI1640 (BioSun), and the CAKI-1 cell line was kept in ATCC-formulated McCoy′s 5A medium (Thermo Fisher). All media were supplemented with 10% foetal bovine serum (FBS) and kept at 37°C in a 5% CO 2 atmosphere.
| MATERIAL S AND ME THODS

| Clinical samples
| Cell culture
| Immunohistochemistry (IHC)
The tissue sections were dried at 60°C for 1 hour and then dewaxed by an automatic dyeing machine. The tissue sections were incubated after being washed with PBS with 3% hydrogen peroxide at room temperature for 6 minutes. The sections were then immersed in 0.01 M 3% citrate buffer. Afterwards, they were heated at 95°C for 10 minutes in a microwave and cooled to room temperature.
After 30 minutes, non-immune goat serum was added and the sections were incubated overnight with BIRC5 (1:1000 v/v) and Ki-67
(1:300 v/v) (Abcam) at 4°C. Afterwards, they were washed in PBS, labelled with HRP-labelled goat anti-rabbit IgG (Abcam) (1:1000 v/v) and incubated for 30 minutes at room temperature. Besides, the sections should be exposed to freshly prepared diaminobenzidine and stained for 4-6 minutes. The sections were also stained for 15 seconds with haematoxylin. Finally, the sections were rinsed with water.
| Quantitative real-time PCR (qRT-PCR)
Total RNA in the RCC tissue samples and tumour cells were extracted with TRIzol reagent (Invitrogen) according to manufacturer's instructions. For each sample, the amount of the total RNA was determined to be 200 ng by a NanoDrop 2000 (Thermo Fisher Scientific). A reverTra Ace qPCR RT Kit was employed for reverse transcription of RNA. Three groups of lncRNAs were calibrated by qRT-PCR using the THUNDERBIRD SYBR® qPCR Mix (Toyobo). The reaction conditions and steps were as follows: 94°C for 2 minutes, 94°C for 10 seconds, 56°C for 30 seconds, 72°C for 1 minute and 72°C for 10 minutes. GAPDH and U6 were used as internal loading controls. qRT-PCR was repeated at least three times. The expression levels of the mRNAs and lncRNAs were normalized against those of GAPDH and relatively quantified using the 2 −ΔΔC t method. The expression of the miRNAs was normalized against that of U6 and relatively quantified using the 2 −ΔΔC t method. All the primers used for qRT-PCR in this study are listed in Table S1 .
| Cell transfection and cultivation
siRNAs for MALAT1 or BIRC5, scrambled siRNAs, miR-203 mimics, miR-203 NC mimics, miR-203 inhibitor and miR-203 NC inhibitor were generated by GenePharma. The pcDNA3.1 plasmid purchased from Thermo Fisher Scientific and employed to overexpress MALAT1 or BIRC5. Before transfection, A498 cells and OS-RC-2 cells were digested with 0.25% trypsin and seeded in 6-well plates (1 × 10 5 cells/ well). When the cells reached 80%-90% confluence, the initial medium was replaced with fresh serum-free medium and antibiotics.
Lipofectamine 2000 (Life Technologies Corporation, Gaithersburg, MD, USA) was used for transfection, and the transfected cells were cultivated at 37°C in a 5% CO 2 atmosphere. The transfection efficiency was detected 48 hours after transfection. The sequences of the siRNA, mimics and inhibitor are given in Table S2 .
| Survival analysis
Survival probabilities were estimated by the Kaplan-Meier plot method according to the website oncLnc (http://www.oncol nc.org/).
We calculated probabilistic survival estimates using probabilitystratified multiplicative statutory laws. The overall survival rate (OS) was predicted through fitting a univariate Cox regression model based on the anatomical stage and Fuhrman scale.
| Dual-luciferase reporter gene assay
The targeted relationship between miR-203 and BIRC5 was pre- Similarly, the pGL3 luciferase reporter gene vector (Promega) loaded with either BIRC5-wt or BIRC5-mut was co-transfected with miR-203 mimics or control into HEK293T cells using Lipofectamine 2000 reagent (Invitrogen). The luciferase activities in cell lysates were measured with a Dual-Glo Luciferase Assay System (Promega) 48 hours after transfection (Promega) in accordance with the manufacturer's instructions. Each experiment was repeated at least three times.
| Cell proliferation (CCK-8) assay
After the cells were transfected for 0, 24, 48 and 72 hours, CCK-8 solution was added (10 μL, Dojindo) to each well. Thereafter, the RCC cells were incubated for 2 hours at 37°C in a 5% CO 2 humidified chamber.
Afterwards, the OD at 450 nm (OD450) was measured with a plate luminometer (Bio-Rad). The experiment was repeated at least three times.
| Flow cytometry analysis
For cell cycle experiments, different groups of cells were collected 72 hours after transfection and digested to obtain a cell suspension.
Cell suspension was centrifuged, and the supernatant was discarded.
Cells were washed twice with PBS to remove any residue and fixed in 
| Wound healing assay
Cell motility was evaluated using a wound healing assay. RCC cells were plated in 24-well plates with serum-free medium until they reached 80% to 90% confluence. The cell monolayers were scratched across the centre of each well with a 10 μL micropipette tip. Wound healing was monitored at the indicated time points by phase-contrast microscopy with a 20 × objective and an inverted microscope. The experiment was performed at least three times.
| Transwell assay
Matrigel (BD Bioscience) and serum-free DMEM were thoroughly mixed and placed in a transwell chamber (Corning Incorporated). Cells at a concentration of 2.5 × 10 4 cells/mL in serum-free medium were placed into the upper chamber (500 μL for each chamber) of 24-well invasion chambers, while culture medium containing 20% FBS was added to the lower chamber. A 4% paraformaldehyde solution was utilized to immobilize the cells, and 0.1% crystal violet was used to stain RCC cells after 24-48 hours of incubation. Pictures were taken of each chamber, and the cells in 5-10 independent fields were counted.
| Western blot analysis
The concentration of each protein was determined using a Pierce BCA Protein Assay Kit (Pierce). After they were separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), the proteins were then transferred to polyvinylidene difluoride membrane (PVDF, Millipore, Billerica) for 120 minutes. Thereafter, membranes were blocked with TBST containing 5% skim milk and incubated with the primary antibody (anti-BIRC5, ab76424, 1:5000; anti-GAPDH, ab181602, 1:10 000). Subsequently, the membranes were incubated with a secondary antibody (anti-rabbit IgG H&L, ab6721, 1:10 000)
for 1 hour at 37°C. All of the antibodies in this study were purchased from Abcam. Signal detection was conducted by the ECL system (Life Technology). The relative protein levels among the samples using the GAPDH density as an internal loading control were compared. 
| Nude mouse tumorigenesis experiment
| Statistical analysis
Data are expressed as mean ± standard deviation (SD) from triplicate independent experiments. Student′s t test was used to compare differences in the two different groups with parametric variables.
For three or more groups, difference analysis was performed by one-way ANOVA. Statistical analysis was carried out with GraphPad Prism 6. P values <0.05 were considered as statistically significant.
| RE SULTS
| BIRC5 was overexpressed in RCC tissues and cells
The mRNA and protein expression of BIRC5 was higher in RCC tissues than in adjacent normal tissues as shown in Figure 1A and it accounts for 10% to 15% of all RCCs. 28 The results of survival analysis illustrated that KIRC and KIRP patients expressing high levels of BIRC5 presented a significantly poorer prognosis than those expressing low levels of BIRC5 ( Figure 1C,D) . In addition, the expression level of BIRC5 in four RCC cell lines (A498, 786-O, OS-RC-2 and CAKI-1) was higher than that in the normal renal cortex proximal tubule epithelial cell line HK-2 ( Figure 1E,F) . In addition, the effects of BIRC5 on cell function were explored. P-BIRC5 upregulated the expression of BIRC5, which was instead downregulated by si-BIRC5-1 and si-BIRC5-2 in both A498 and OS-RC-2 cell lines ( Figure S1A-B) .
Given that the knockdown efficiency was higher in the si-BIRC5-2 group than in the si-BIRC5-1 group, si-BIRC5-2 was utilized for further studies. Taken together, these data suggest that BIRC5 was overexpressed in RCC tissues and cells, and BIRC5 promoted the development and progression of RCC cells.
F I G U R E 1 BIRC5 expression was higher in RCC tissues and cell lines than in control tissues and cell lines. A, The expression of BIRC5 was higher in RCC tissues than in adjacent normal tissues, as shown by qRT-PCR. B, IHC results showed that the expression of BIRC5 was higher in RCC tissues than in adjacent normal tissues. C and D, Kaplan-Meier plot analysis illustrated that patients expressing high levels of BIRC5 presented a significantly poorer prognosis than those expressing low levels of BIRC5. E and F, The increased expression levels of BIRC5 were detected in four RCC cell lines (A498, 786-O, OS-RC-2 and CAKI-1) compared with its expression in a normal renal cortex proximal tubule epithelial cell line. Data were expressed as mean ± standard deviation of three independent experiments. **P < 0.01. ***P < 0.001
| MiR-203 directly targeted BIRC5 and suppressed the expression of BIRC5
The miRanda database predicted that that BIRC5 is a potential target of miR-203 ( Figure 2A ). To verify the targeted relationship, a dual-luciferase reporter gene assay was employed. Dual-luciferase reporter gene assay showed that the luciferase activity of the group co-transfected with miR-203 mimics and BIRC5-wt was lower than that of the group co-transfected with miR-203 NC and BIRC5-wt Figure S3B ). In brief, miR-203 directly targeted BIRC5 and suppressed its expression in RCC.
| Effects of miR-203 on cell proliferation, cell cycle, apoptosis and migration of RCC cells
The CCK-8 assay indicated that the overexpression of miR-203 significantly decreased cell viability, which was instead increased with downregulation of miR-203 in both A498 and OS-RC-2 cells ( Figure 3A 
| Targeted relationship between miR-203 and MALAT1 was validated
Two potential binding sites between MALAT1 and miR-203 were identified based on starBase as shown in Figure 4A . 
| Effects of MALAT1 on the proliferation, cell cycle, apoptosis and migration of RCC cells
The CCK-8 assay indicated that the upregulation of MALAT1 significantly increased cell viability, which was otherwise decreased with downregulation of MALAT1 in both A498 and OS-RC-2 cells ( Figure 6A 
| MALAT1 promoted RCC tumorigenesis in vivo
As shown in Figure 7A 
| D ISCUSS I ON
LncRNAs are important regulators of gene expression that interact with major signalling pathways for cell growth, proliferation, differentiation, apoptosis, migration, and invasion. 29 In some studies, MALAT1 acted as an miR-203 sponges to promote inflammation in myocardial ischaemia-reperfusion injury. 30 In our study, MALAT1 BIRC5 has been shown to inhibit cell apoptosis yet promote cell proliferation in human cancers. The overexpression of BIRC5 was observed in almost all human malignancies, and the increased expression of BIRC5 was correlated with poor clinical outcomes, tumour recurrence and drug resistance in cancer patients. 31 Recently, increasing numbers of studies have showed that BIRC5 is regulated by cytokines in lymphocytes and plays a vital role in the proliferation and survival of haematopoietic cells. 32 We verified that BIRC5 accelerated cell proliferation and the cell cycle, inhibited apoptotic pathways and promoted cell migration. Some articles also showed that BIRC5 inhibited caspase-dependent apoptotic pathways and caspase-independent apoptotic pathways as well as accelerated cell proliferation. 20 We investigated proposed targeted relationship between miR-203 and BIRC5. Our results showed that the overexpression of miR-203 inhibited BIRC5 expression, while the inhibition of an miR-203 inhibitor accelerated BIRC5 expression. Wang et al demonstrated that miR-203 suppressed the proliferation and migration of lung cancer cells and promoted their apoptosis by targeting SRC. 30 Zhang et al suggested that miR-203 inhibited tumour growth and invasion in oesophageal cancer by inhibiting Ran. 6 These studies are generally consistent with our results. In addition, we verified that miR-203 inhibited cell proliferation, cell cycle progression and cell migration but promoted apoptotic pathways by targeting BIRC5.
Moreover, MALAT1 was shown to be upregulated in RCC.
MALAT1 upregulated BIRC5 expression to promote cell proliferation, cell cycle progression and migration yet inhibited cell apoptosis in RCC through targeting miR-203. Besides, MALAT1 promoted OS tumour growth in vivo. 33, 34 Furthermore, MALAT1 regulated ovarian cancer cell proliferation, migration and apoptosis through Wnt/βcatenin signalling pathway. 35 Our research showed that MALAT1 promoted RCC tumorigenesis in vitro. We validated that the expression level of MALAT1 was higher in RCC tissues and cell lines than in adjacent normal tissues and a normal renal cortex proximal tubule epithelial cell line.
RCC patients with high MALAT1 expression had more advanced clinical features and a shorter overall survival time than those with low MALAT1 expression. 36 MALAT1 promoted cancer cell proliferation and metastasis through activating the ERK/MAPK pathway and interacting with hnRNP during cell cycle regulation. 19 In the same way, our study explored the mechanism of action between them.
To conclude, we confirmed the direct targeted relationships between MALAT1 and miR-203, as well as miR-203 and BIRC5. Besides, the downregulation of MALAT1 significantly increased the expression of miR-203, which was consistent with the results of Chen et al 37 However, upregulation of MALAT1 greatly decreased the expression of miR-203. MALAT1 regulated hypoxia-induced angiogenesis, activated ERK/MAPK signal transduction and eliminated anti-hypertrophic microRNA-133. 38 However, the limitations of this study should be taken into account. It was of great importance to detect relevant factors or signalling pathways that could be employed for further validation of significant roles of MALAT1/miR-203/BIRC5 in RCC. In our study, the expression of both survivin and cell proliferation marker Ki67 was detected by IHC as shown in Figures 1B and 7G , respectively, to validate the significant roles of MALAT1/miR-203/ BIRC5 in the development and progression of renal cell carcinoma. However, other relevant markers and pathways, such as caspase 3/9, cyclins or EMT, will be measured and validated in further studies. In addition, uncovering more targets of miR-203 in RCC could facilitate therapeutic intervention in the future. Furthermore, MALAT1 was reported to be closely related to the development and progression of a variety of human cancers. MALAT1 was reported to be overexpressed in several kinds of human cancers, such as osteosarcoma, 34 lung cancer 39 and colorectal cancer. 40 The detection of MALAT1
has not yet been utilized for the diagnosis and treatment of RCC.
However, upgraded and integrated therapies could be developed based on the detection of MALAT1. More miRNAs specifically targeting MALAT1 in RCC needed to be uncovered for the development of integrated therapies. In addition, more specific mRNAs regulated by MALAT1 in RCC could be selected as potential therapeutic targets.
In conclusion, MALAT1 accelerates the development and progression of renal cell carcinoma by decreasing the expression of miR-203 and promoting the expression of BIRC5.
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